Driving Strategic Clarity, Value and Growth
Strategic Counsel Rooted in Rigorous Analytics
From early-stage candidates to brand leaders in biopharmaceutical and medical technology, we work across every phase of your products’ lifecycle to maximize your commercial, R&D, corporate and business development opportunities.
Our formula for success:
- Start with a deep dive into the data
- Apply robust qualitative and quantitative analytics
- Leverage vast scientific, clinical, commercial, and transactional expertise
- Senior leadership involvement from project concept through delivery
The result: Clarity out of ambiguity — driving actionable growth strategies.
Investment Banking Powered by Research-Driven Insight
The Back Bay Life Science Advisors approach:
Back Bay combines insights generated from in-depth scientific, clinical, and commercial analysis with exceptional transaction execution capabilities to provide our clients with tailored, sound advice on realizing value.
Our offerings include:
- Mergers, acquisitions and divestitures
- Cross-border transactions
- Structured transactions involving complex options
- Financing support
- Valuation and fairness opinions
The result: Seamless integration from asset valuation and positioning through to successful deal execution – a formula for maximizing value in a smooth, efficient process.
Results Matter: See what our clients say
Since 2010, Back Bay has driven hundreds of client engagements to a successful outcome. Our team consistently leverages realistic growth strategies for Back Bay clients across a wide range of therapeutic areas and business needs.
"Working with Back Bay Life Sciences has been an important part of our Business Development effort. They deliver the highest quality work from asset identification and screening, through deeper evaluation and diligence... I could not be more pleased with the work Back Bay has provided us and could not recommend them more highly."
"I have worked with Back Bay on a number of assignments and find it unique and very valuable to be able to work with the same advisors from the development of the business strategy though to the transaction process . The continuity throughout the process has been essential for an effective process and of course a successful transaction."
“The BB team really helped us answer some difficult questions. Great insights intelligently delivered.”
“Back Bay has helped us, quickly, efficiently, and with great expertise, to explore new solutions and opportunities as well as execute in critical transactional circumstances. The Back Bay Team has been great to work with.”
Jonathan Gertler Interview on The Bloomberg Baystate Business Hour
19 APRIL 2017
Back Bay Life Science Advisors CEO Jonathan Gertler joined anchor Anne Mostue on The Bloomberg Baystate Business Hour to discuss Convergence Forum, the annual ideas exchange on the future of healthcare from biotech leaders around greater New England.
Michelle Hoffmann Interviewed by Healthcare Innovation News
11 APRIL 2017
BBLSA Senior Vice President, Strategy Consulting, Michelle Hoffman provided insight in the April issue of Healthcare Innovation News, “How Do You Build a Culture of Innovation Within Your Organization?”
Stephan Gauldie Blog Published on Becker’s Hospital Review
23 MARCH 2017
How long before the biosimilar market looks like the generics market?
While still a relatively new area of biopharma, the biosimilar market has been getting more and more competitive, with huge pipelines of products in development, and a multitude of candidates targeting each of the major blockbuster biologic brands.